Impact News +++ Is AEVA′s Record Q2 Revenues the Spark for Lasting Growth? (Zacks) +++ AEVA Aktie -3,86%

SYNDAX Aktie

>SYNDAX Aktienkurs

13.7 EUR +0.0% (Tradegate)

Ask: 14 EUR / 860 Stück

Bid: 13.8 EUR / 880 Stück

Tagesumsatz: 10 Stück

Realtime Kurs von 8 bis 22 Uhr!

SYNDAX Aktie über LYNX handeln

Intraday

1 Jahr

>SYNDAX Performance

1 Woche: +7,9%

1 Monat: +60,9%

3 Monate: +51,1%

6 Monate: -15,5%

1 Jahr: -25,3%

laufendes Jahr: +11,0%

>SYNDAX Aktie

Name:

SYNDAX PHARMACEU.DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US87164F1057 / A2AFL6

Symbol/ Ticker:

1T3 (Frankfurt) / SNDX (NASDAQ)

Kürzel:

FRA:1T3, ETR:1T3, 1T3:GR, NASDAQ:SNDX

Index:

Webseite:

https://www.syndax.com/

Profil:

Syndax Pharmaceuticals Inc. is a biopharmaceutical..
>Volltext..

Marktkapitalisierung:

1138.09 Mio. EUR

Unternehmenswert:

1045.02 Mio. EUR

Umsatz:

67.09 Mio. EUR

EBITDA:

-290.76 Mio. EUR

Nettogewinn:

-287.48 Mio. EUR

Gewinn je Aktie:

-3.35 EUR

Schulden:

296.52 Mio. EUR

Liquide Mittel:

93.23 Mio. EUR

Operativer Cashflow:

-259.75 Mio. EUR

Bargeldquote:

4.03

Umsatzwachstum:

1931.07%

Gewinnwachstum:

-15.34%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 875.099 USD.

Suchwörter:

SYNDAX

Letzte Datenerhebung:

22.08.25

>SYNDAX Kennzahlen

Aktien/ Unternehmen:

Aktien: 86.14 Mio. St.

Frei handelbar: 96.73%

Leerverk. Aktien: 28%

Rückkaufquote: -0.63%

Mitarbeiter: 270

Umsatz/Mitarb.: 0.08 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 130.93%

Bewertung:

KGV: -

KGV lG: -

KUV: 17.23

KBV: 8.69

PEG-Ratio: -0.26

EV/EBITDA: -

Rentabilität:

Bruttomarge: 96.17%

Gewinnmarge: -428.48%

Operative Marge: -433.37%

Managementeffizenz:

Gesamtkaprendite: -62.43%

Eigenkaprendite: -113.22%

>SYNDAX Peer Group

Es sind 601 Aktien bekannt.

>SYNDAX Chart & Kurs - NASDAQ

>SYNDAX News

19.08.25 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 304170 USD (Insiderkauf)
	Podlesak, Dennis - Aufsichtsrat - Tag der Transaktion: 2025-08-18...

19.08.25 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 272521 USD (Insiderkauf)
	Podlesak, Dennis - Aufsichtsrat - Tag der Transaktion: 2025-08-14...

19.08.25 - 01:01	Insiderhandel: Aufsichtsrat verkauft Aktien von Syndax Pharmaceuticals im Wert von 298408 USD (Insiderkauf)
	Podlesak, Dennis - Aufsichtsrat - Tag der Transaktion: 2025-08-15...

14.08.25 - 17:30	Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? (Zacks)
	The mean of analysts' price targets for Syndax (SNDX) points to a 158.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

06.08.25 - 22:03

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2025 the Company granted inducement awards to purchase up to 48,600 shares of common stock to seven new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates....

05.08.25 - 05:54	Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

05.08.25 - 00:24	Syndax (SNDX) Q2 Revenue Jumps 986% (Fool)
	Um den gesamten Artikel unter fool.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 22:51	Syndax Pharmaceuticals GAAP EPS of -$0.83 beats by $0.18, revenue of $37.96M beats by $11.32M (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

04.08.25 - 22:03	Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire EN)
	– $28.6 million of Revuforj® (revumenib) net revenue, representing 43% growth over 1Q25 –...

01.08.25 - 23:51	Syndax Pharmaceuticalss Earnings: A Preview (Benzinga)
	read more...

01.08.25 - 23:42	Syndax Pharmaceuticals Q2 2025 Earnings Preview (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.07.25 - 19:45	All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy (Zacks)
	Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

28.07.25 - 13:03	Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025 (GlobeNewswire EN)
	NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025....

24.07.25 - 10:01	iOnctura Strengthens Medical and Commercialization Expertise with Two Non-Executive Board Appointments (PR Newswire)
	Neil Gallagher M.D., Ph.D., former AbbVie Chief Medical Officer and President of R&D at Syndax, brings considerable experience in oncology drug development Anthony Mancini, currently Global Chief Commercial Officer at Revolution Medicines, led several successful oncology product launches......

19.07.25 - 03:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 12033 USD (Insiderkauf)
	Goldan, Keith A. - Vorstand - Tag der Transaktion: 2025-07-16...

19.07.25 - 03:01	Insiderhandel: Chief Executive Officer verkauft Aktien von Syndax Pharmaceuticals im Wert von 69953 USD (Insiderkauf)
	Metzger, Michael A. - Vorstand - Tag der Transaktion: 2025-07-16...

02.07.25 - 22:03

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire EN)

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates....

24.06.25 - 22:03	Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia (GlobeNewswire EN)
	– PDUFA action date set for October 25, 2025 –...

12.06.25 - 18:06	Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025 (GlobeNewswire EN)
	– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –...

12.06.25 - 13:03	Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025 (GlobeNewswire EN)
	– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population –...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Das nackte Kind, das zagt nicht; mit seinem Pfennig springt es fort und kennt recht gut den Sammelort - ich meine des Bäckers Laden. - Johann Wolfgang von Goethe

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram